Sugiura et al., 2002 - Google Patents
Interference between D30N and L90M in selection and development of protease inhibitor-resistant human immunodeficiency virus type 1Sugiura et al., 2002
View PDF- Document ID
- 9854235062567836205
- Author
- Sugiura W
- Matsuda Z
- Yokomaku Y
- Hertogs K
- Larder B
- Oishi T
- Okano A
- Shiino T
- Tatsumi M
- Matsuda M
- Abumi H
- Takata N
- Shirahata S
- Yamada K
- Yoshikura H
- Nagai Y
- Publication year
- Publication venue
- Antimicrobial agents and chemotherapy
External Links
Snippet
We studied the evolutionary relationships between the two protease inhibitor (PI) resistance mutations, D30N and L90M, of human immunodeficiency virus type 1 (HIV-1). The former is highly specific for nelfinavir resistance, while the latter is associated with resistance to …
- 102200087207 SMN2 D30N 0 title abstract description 136
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriphage
- C12Q1/701—Specific hybridization probes
- C12Q1/702—Specific hybridization probes for retroviruses
- C12Q1/703—Viruses associated with AIDS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse Transcribing RNA Viruses
- C12N2740/00011—Reverse Transcribing RNA Viruses
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sugiura et al. | Interference between D30N and L90M in selection and development of protease inhibitor-resistant human immunodeficiency virus type 1 | |
| Wainberg et al. | The impact of HIV genetic polymorphisms and subtype differences on the occurrence of resistance to antiretroviral drugs | |
| Troyer et al. | Changes in human immunodeficiency virus type 1 fitness and genetic diversity during disease progression | |
| Gong et al. | In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632 | |
| Brenner et al. | Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection | |
| Mammano et al. | Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients | |
| Rodés et al. | Emergence of drug resistance mutations in human immunodeficiency virus type 2-infected subjects undergoing antiretroviral therapy | |
| Ruff et al. | Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure | |
| Hachiya et al. | Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors | |
| Raugi et al. | Complex patterns of protease inhibitor resistance among antiretroviral treatment-experienced HIV-2 patients from Senegal: implications for second-line therapy | |
| Ntemgwa et al. | Antiretroviral drug resistance in human immunodeficiency virus type 2 | |
| Masquelier et al. | Genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 variants with insertions or deletions in the reverse transcriptase (RT): multicenter study of patients treated with RT inhibitors | |
| Ntemgwa et al. | Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors | |
| Watkins et al. | Selection of high-level resistance to human immunodeficiency virus type 1 protease inhibitors | |
| Kijak et al. | Origin of human immunodeficiency virus type 1 quasispecies emerging after antiretroviral treatment interruption in patients with therapeutic failure | |
| Diamond et al. | Islatravir has a high barrier to resistance and exhibits a differentiated resistance profile from approved nucleoside reverse transcriptase inhibitors (NRTIs) | |
| Tanuri et al. | Genetic variation and susceptibilities to protease inhibitors among subtype B and F isolates in Brazil | |
| Lihana et al. | HIV type 1 subtype diversity and drug resistance among HIV type 1-infected Kenyan patients initiating antiretroviral therapy | |
| de la Carrière et al. | Effects of human immunodeficiency virus type 1 resistance to protease inhibitors on reverse transcriptase processing, activity, and drug sensitivity | |
| Sahu et al. | Recovery of replication-competent residual HIV-1 from plasma of a patient receiving prolonged, suppressive highly active antiretroviral therapy | |
| Santos et al. | Effect of natural polymorphisms in the HIV-1 CRF02_AG protease on protease inhibitor hypersusceptibility | |
| Gao et al. | Characterization of a subtype D human immunodeficiency virus type 1 isolate that was obtained from an untreated individual and that is highly resistant to nonnucleoside reverse transcriptase inhibitors | |
| Doualla-Bell et al. | Impact of human immunodeficiency virus type 1 subtype C on drug resistance mutations in patients from Botswana failing a nelfinavir-containing regimen | |
| Larrouy et al. | Gag mutations can impact virological response to dual-boosted protease inhibitor combinations in antiretroviral-naive HIV-infected patients | |
| Lisovsky et al. | HIV-1 protease codon 36 polymorphisms and differential development of resistance to nelfinavir, lopinavir, and atazanavir in different HIV-1 subtypes |